Enovix (NASDAQ:ENVX – Get Free Report) had its target price reduced by analysts at JPMorgan Chase & Co. from $18.00 to $15.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 31.12% from the company’s current price.
Several other equities research analysts also recently commented on ENVX. Benchmark assumed coverage on Enovix in a report on Monday, July 22nd. They set a “buy” rating and a $25.00 target price for the company. B. Riley upgraded shares of Enovix to a “strong-buy” rating in a research report on Tuesday, June 25th. Piper Sandler reiterated an “overweight” rating and set a $19.00 price objective (down from $23.00) on shares of Enovix in a research report on Monday, August 5th. TD Cowen increased their target price on Enovix from $11.00 to $14.00 and gave the company a “hold” rating in a report on Thursday, August 1st. Finally, Craig Hallum lifted their price target on Enovix from $15.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, August 1st. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Enovix has a consensus rating of “Buy” and a consensus target price of $21.67.
Read Our Latest Research Report on ENVX
Enovix Price Performance
Enovix (NASDAQ:ENVX – Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $3.77 million during the quarter, compared to analysts’ expectations of $3.85 million. Enovix had a negative net margin of 1,434.34% and a negative return on equity of 91.21%. As a group, equities analysts anticipate that Enovix will post -1.21 EPS for the current fiscal year.
Insider Buying and Selling at Enovix
In other news, insider Arthi Chakravarthy sold 35,000 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $13.00, for a total transaction of $455,000.00. Following the completion of the sale, the insider now directly owns 343,305 shares of the company’s stock, valued at $4,462,965. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 15.70% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of ENVX. Vanguard Group Inc. increased its position in Enovix by 1.3% during the first quarter. Vanguard Group Inc. now owns 13,093,710 shares of the company’s stock worth $104,881,000 after buying an additional 164,717 shares during the last quarter. Driehaus Capital Management LLC increased its holdings in shares of Enovix by 63.7% during the 2nd quarter. Driehaus Capital Management LLC now owns 3,886,492 shares of the company’s stock valued at $60,085,000 after acquiring an additional 1,512,424 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Enovix by 2,228.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,438,011 shares of the company’s stock valued at $11,518,000 after acquiring an additional 1,376,253 shares in the last quarter. Masters Capital Management LLC lifted its holdings in Enovix by 3.8% in the 1st quarter. Masters Capital Management LLC now owns 1,350,000 shares of the company’s stock worth $10,814,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Old West Investment Management LLC boosted its position in Enovix by 47.6% during the second quarter. Old West Investment Management LLC now owns 835,386 shares of the company’s stock worth $12,915,000 after purchasing an additional 269,371 shares during the period. Institutional investors own 50.92% of the company’s stock.
About Enovix
Enovix Corporation designs, develops, and manufactures lithium-ion batteries. It serves wearables and IoT, smartphone, laptops and tablets, industrial and medical, and electric vehicles industries. The company was founded in 2007 and is headquartered in Fremont, California.
Featured Articles
- Five stocks we like better than Enovix
- Consumer Staples Stocks, Explained
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- The Basics of Support and Resistance
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Ride Out The Recession With These Dividend KingsĀ
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Enovix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovix and related companies with MarketBeat.com's FREE daily email newsletter.